| HOME >> BIOLOGY >> TECHNOLOGY |
New Consulting Unit Hosts Three Customer Audits, Continues Growth Strategy
That Leverages Pharsight's Industry-Leading Software Tools
MOUNTAIN VIEW, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that three global biopharmaceutical companies have performed audits of its Reporting and Analysis Services (RAS) unit. The three global drug development organizations that have performed audits of the RAS unit's capabilities are a Top 50 pharmaceutical company, a mid-sized specialty pharmaceutical company, and a leading biotechnology company.
The audits covered RAS operating practices and procedures for study analysis and reporting, RAS facilities, and RAS technology infrastructure. The ability of the RAS unit to support customer quality assurance audits underscores the unit's recently expanded quality assurance capabilities, and reflects the establishment of its quality management infrastructure which expands the types of services RAS can provide to Pharsight customers.
The RAS unit provides pharmacokinetic/pharmacodynamic (PK/PD) analysis and reporting for preclinical and clinical studies, utilizing Pharsight's industry-leading modeling, data management and reporting software tools to provide timely, high-quality analyses supporting sponsors' new drug application submissions. To date RAS has signed consulting agreements for PK/PD analysis and reporting and for population pharmacokinetic modeling with more than 20 pharmaceutical and biotechnology companies.
Since its launch in May 2007, the RAS unit has implemented and
validated Pharsight's Win
'/>"/>
| SOURCE Pharsight Corporation Copyright©2007 PR Newswire. All rights reserved |